• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

Log in
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
www.sages.org

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • MIS Fellows Course
      • SAGES Robotics Residents and Fellows Courses
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • OWLS/FLS
You are here: Home / Abstracts / PLASMA LEVELS OF SERPIN E1, A TUMORGENIC PROTEIN, ARE PERSISTENTLY ELEVATED DURING THE FIRST MONTH AFTER MINIMALLY INVASIVE COLORECTAL CANCER RESECTION WHICH MAY SUPPORT RESIDUAL TUMOR GROWTH AND METASTASIS.

PLASMA LEVELS OF SERPIN E1, A TUMORGENIC PROTEIN, ARE PERSISTENTLY ELEVATED DURING THE FIRST MONTH AFTER MINIMALLY INVASIVE COLORECTAL CANCER RESECTION WHICH MAY SUPPORT RESIDUAL TUMOR GROWTH AND METASTASIS.

H M C Shantha Kumara, PhD, Carl S Winkler, MD, Erica Pettke, MD, Sandhu K Jaspreet, MD, Simon Tian, BS, Abhinit Shah, MBBS, Xiaohong Yan, PhD, Cekic Vesna, RN, Nipa D Gandhi, MD, Richard L Whelan, MD. Mout Sinai West, New York USA

Introduction: Serpin E1, also known as Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of urokinase type plasminogen activator (uPA) and tissue-type plasminogen activators (tPA ) .  PAI-1 plays a role in the regulation of angiogenesis, wound healing, and tumor cell invasion; over expression has been noted in breast, esophageal, and colorectal cancer (CRC).  PAI-1 is also a potent regulator of endothelial cell (EC) proliferation and migration in vitro and of angiogenesis and tumor growth in vivo. The plasminogen/plasmin system plays a key role in cancer progression by mediating extracellular matrix degradation and tumor cell migration.  Surgery’s impact on plasma PAI-1 levels is unknown. This study’s purpose was to measure plasma PAI-1 levels before and during the first month after minimally invasive colorectal resection (MICR) for CRC.

Method: CRC patients who had MICR who were enrolled in an IRB approved data/plasma bank for whom adequate plasma samples were available were eligible. Clinical and pathologic data were reviewed. Only patients for whom preoperative (PreOp), postoperative day (POD) 1, POD 3 and at least 1 late postop plasma sample (POD 7-34) were available were studied.  Late samples were bundled into 7 day time blocks and considered as single time points.  Plasma was isolated and stored at -80°C. PAI-1 levels were determined in duplicate via ELISA and the results reported as mean ±SD. The Wilcoxon paired t-test was used for analysis (significance, p<0.05).

Results: 91 MICR CRC patients (colon 73%; rectal 27%; 45 male /46 female, mean age 67.3± 13.6 years) were studied. The mean incision length was 8.0±3.9 cm and mean length of stay was 6.8± 4.3days. The final cancer stage breakdown follows; I (n=30), II (n=30), III (n=36) and IV (n=4). %.  When compared to mean Preop levels (18.5±8.3 ng/ml), significantly elevated mean levels (ng/ml) were noted on POD 1 (32.2± 22.4; n=91,p<0.001), POD 3 (22.9±13.1,n=86,p=0.003), POD7-13 (30.2±17.5, n=65,p<0.001), and POD14-20 (28.5±16.4,n=26,p=0.001) , POD 21-27(28.2±15.8, n=19,p<0.001) and There was no significant difference noted between the POD 27-34 and PreOp results.

Conclusion: Plasma PIA-1 levels are significantly elevated vs. Preop levels for 1 month after MICR for CRC. The early increase after MICR may be related to the acute inflammatory response via macrophage activation.  The elevation noted during weeks 2-4, however, may be related to PAI-1 associated VEGF induced angiogenesis occurring in the healing wounds; these plasma changes may also promote angiogenesis in residual tumor deposits.  Further studies are warranted.  


Presented at the SAGES 2017 Annual Meeting in Houston, TX.

Abstract ID: 85098

Program Number: P214

Presentation Session: iPoster Session (Non CME)

Presentation Type: Poster

26

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Mastodon (Opens in new window) Mastodon
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on Bluesky (Opens in new window) Bluesky

Related


sages_adbutler_leaderboard

Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064

1-310-437-0544

[email protected]

Monday – Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Bluesky
  • X
  • Instagram
  • Facebook
  • YouTube

Copyright © 2025 · SAGES · All Rights Reserved

Important Links

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals